Business
4D Molecular Therapeutics Reports Second Quarter 2022 Financial Results and Provides 4D-310 Program Update
- Five clinical-stage product candidates on track for multiple clinical data updates in 2023 - Cash, cash equivalents and marketable securities sufficient to
About this update from 4d Molecular Therapeutics, Inc.
[{"type":"text","content":"- Five clinical-stage product candidates on track for multiple clinical data updates in 2023 - Cash, cash equivalents and marketable securities sufficient to fund operations into the first half of 2025 - 4D-310 Phase 1/2 clinical trial eligible patient population expanded to include females with Fabry disease EMERYVILLE, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, reported second quarter 2022 financial results and provided a 4D-310 program update. \"Maintaining our momentum from the first quarter, we continued to execute towards our clinical and corporate milestones, including progress across all of our five clinical-stage product candidates,” said David Kirn, M.D., Co-founder, President and Chief Executive Officer of 4DMT. “In addition, the protocol amendment for the 4D-310 Phase 1/2 clinical trial in Fabry disease will expand access to include female patients, a large and significantly affected patient population with Fabry disease. We have maintained our focus on efficient cash utilization, with current cash available to support our operations into the first half of 2025. Our team is committed to relentless execution as we make progress toward key clinical data readouts in the first half of 2023 and beyond.” Update on 4D-310 Phase 1/2 Clinical Trial for Fabry Disease In June 2022, 4DMT filed a protocol amendment with the U.S. Food and Drug Administration (FDA) for the ongoing Phase 1/2 clinical trial of 4D-310 for Fabry disease. The protocol amendment is intended to expand the eligible patient population, including the addition of female Fabry patients with symptomatic disease. The inclusion of female patients in the phase 1/2 clinical trial was supported by clinical experience to-date, as well as a GLP toxicology study in female mice. The company continues to expect to provide a clinical data update on 4D-310 in the 1st half of 2023. Second Quarter 2022 Financial Results Cash, Cash Equivalents and Marketable Securities: Cash, cash equivalents and marketable securities were $261.6 million as of June 30, 2022. We expect cash, cash equivalents and marketable securities to be sufficient to fund operations into the first half of 2025. Revenue: Total revenue for the quart...